Amylyx Pharmaceuticals, Inc. AMLX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s total current liabilities?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported total current liabilities of $15.97M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s total current liabilities decreased by 11.0% year-over-year, from $17.93M to $15.97M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total current liabilities?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s total current liabilities has grown at a 6.9% compound annual growth rate (CAGR), from $17.4M to $22.69M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.